Everyday Health on MSN
What Is Nerandomilast (Jascayd)?
Nerandomilast (Jascayd) is a new FDA-approved treatment for IPF, slowing disease progression. Learn about its uses, side ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today ...
Ingelheim, Germany/Ridgefield, Connecticut, U.S. Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults ...
2d
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the ...
TipRanks on MSN
PureTech Health presents new analyses from ELEVATE IPF trial
PureTech Health (PRTC) announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone for the treatment of ...
CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...
Patients with IPF and emphysema who received antifibrotic agents had similar outcomes to patients with IPF alone.
This optimized preclinical model is positioned to expand research opportunities in the fight against lung disease. By reducing the mortality rate from an industry average of 40% to 20%, we provide ...
Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback